Mark Cooper

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Immunohistochemistry

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Koh Philip J W; Koitka Audrey; Cooper Mark E; Allen Terri J
Eplerenone does not attenuate diabetes-associated atherosclerosis.
Chew Phyllis; Yuen Derek Y C; Koh Philip; Stefanovic Nada; Febbraio Mark A; Kola Ismail; Cooper Mark E; de Haan Judy B
Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse.
Coughlan Melinda T; Thorburn David R; Penfold Sally A; Laskowski Adrienne; Harcourt Brooke E; Sourris Karly C; Tan Adeline L Y; Fukami Kei; Thallas-Bonke Vicki; Nawroth Peter P; Brownlee Michael; Bierhaus Angelika; Cooper Mark E; Forbes Josephine M
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Mark Cooper (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Koh Philip J W; Koitka Audrey; Cooper Mark E; Allen Terri J
Eplerenone does not attenuate diabetes-associated atherosclerosis.
Journal of hypertension 2009;27(7):1431-8.
2009: Chew Phyllis; Yuen Derek Y C; Koh Philip; Stefanovic Nada; Febbraio Mark A; Kola Ismail; Cooper Mark E; de Haan Judy B
Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse.
Arteriosclerosis, thrombosis, and vascular biology 2009;29(6):823-30.
2009: Coughlan Melinda T; Thorburn David R; Penfold Sally A; Laskowski Adrienne; Harcourt Brooke E; Sourris Karly C; Tan Adeline L Y; Fukami Kei; Thallas-Bonke Vicki; Nawroth Peter P; Brownlee Michael; Bierhaus Angelika; Cooper Mark E; Forbes Josephine M
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.
Journal of the American Society of Nephrology : JASN 2009;20(4):742-52.
2009: Soldatos Georgia; Cooper Mark E
Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?
Nature clinical practice. Endocrinology & metabolism 2009;5(3):138-9.
2008: Goh Su-Yen; Jasik Mariusz; Cooper Mark E
Agents in development for the treatment of diabetic nephropathy.
Expert opinion on emerging drugs 2008;13(3):447-63.
2008: Calkin A C; Giunti S; Sheehy K J; Chew C; Boolell V; Rajaram Y S; Cooper M E; Jandeleit-Dahm K A
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Diabetologia 2008;51(9):1731-40.
2008: Soro-Paavonen Aino; Watson Anna M D; Li Jiaze; Paavonen Karri; Koitka Audrey; Calkin Anna C; Barit David; Coughlan Melinda T; Drew Brian G; Lancaster Graeme I; Thomas Merlin; Forbes Josephine M; Nawroth Peter P; Bierhaus Angelika; Cooper Mark E; Jandeleit-Dahm Karin A
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.
Diabetes 2008;57(9):2461-9.
2008: Tikellis Christos; Thomas Merlin C; Harcourt Brooke E; Coughlan Melinda T; Pete Josepha; Bialkowski Katarzyna; Tan Adeline; Bierhaus Angelika; Cooper Mark E; Forbes Josephine M
Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.
American journal of physiology. Endocrinology and metabolism 2008;295(2):E323-30.
2008: Barit David; Cooper Mark E
Diabetic patients and kidney protection: an attainable target.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2008;26(2):S3-7.
2008: Barit David; Cooper Mark E
Diabetic patients and kidney protection: an attainable target.
Journal of hypertension 2008;26 Suppl 2():S3-7.
2008: Forbes Josephine M; Coughlan Melinda T; Cooper Mark E
Oxidative stress as a major culprit in kidney disease in diabetes.
Diabetes 2008;57(6):1446-54.
2008: Sourris Karly C; Forbes Josephine M; Cooper Mark E
Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?
Annals of the New York Academy of Sciences 2008;1126():101-6.
2008: Koitka A; Cooper M E; Thomas M C; Tikellis C
Angiotensin converting enzyme 2 in the kidney.
Clinical and experimental pharmacology & physiology 2008;35(4):420-5.
2008: Tikellis Chris; Bialkowski Katarzyna; Pete Josepha; Sheehy Karen; Su Qui; Johnston Colin; Cooper Mark E; Thomas Merlin C
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes.
Diabetes 2008;57(4):1018-25.
2008: Goh Su-Yen; Cooper Mark E
Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
The Journal of clinical endocrinology and metabolism 2008;93(4):1143-52.
2008: Thallas-Bonke Vicki; Thorpe Suzanne R; Coughlan Melinda T; Fukami Kei; Yap Felicia Y T; Sourris Karly C; Penfold Sally A; Bach Leon A; Cooper Mark E; Forbes Josephine M
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Diabetes 2008;57(2):460-9.
2008: McRobert E Anne; Tikoo Anjali; Cooper Mark E; Bach Leon A
Localization of the ezrin binding epitope for advanced glycation endproducts.
The international journal of biochemistry & cell biology 2008;40(8):1570-80.
2007: Coughlan M T; Forbes J M; Cooper M E
Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes.
Kidney international. Supplement 2007;(106):S54-60.
2007: Hoang A; Murphy A J; Coughlan M T; Thomas M C; Forbes J M; O'Brien R; Cooper M E; Chin-Dusting J P F; Sviridov D
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.
Diabetologia 2007;50(8):1770-9.
2007: Lassila M; Fukami K; Jandeleit-Dahm K; Semple T; Carmeliet P; Cooper M E; Kitching A R
Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease.
Diabetologia 2007;50(6):1315-26.
2007: Lewis Paul; Stefanovic Nada; Pete Josefa; Calkin Anna C; Giunti Sara; Thallas-Bonke Vicki; Jandeleit-Dahm Karin A; Allen Terri J; Kola Ismail; Cooper Mark E; de Haan Judy B
Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
Circulation 2007;115(16):2178-87.
2007: Tan Adeline L Y; Forbes Josephine M; Cooper Mark E
AGE, RAGE, and ROS in diabetic nephropathy.
Seminars in nephrology 2007;27(2):130-43.
2007: Coughlan Melinda T; Cooper Mark E; Forbes Josephine M
Renal microvascular injury in diabetes: RAGE and redox signaling.
Antioxidants & redox signaling 2007;9(3):331-42.
2007: Forbes J M; Fukami K; Cooper M E
Diabetic nephropathy: where hemodynamics meets metabolism.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(2):69-84.
2007: Coughlan Melinda T; Thallas-Bonke Vicki; Pete Josefa; Long David M; Gasser Anna; Tong David C K; Arnstein Maryann; Thorpe Suzanne R; Cooper Mark E; Forbes Josephine M
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Endocrinology 2007;148(2):886-95.
2007: Calkin A C; Jandeleit-Dahm K A; Sebekova E; Allen T J; Mizrahi J; Cooper M E; Tikellis C
PPARs and diabetes-associated atherosclerosis.
Current pharmaceutical design 2007;13(26):2736-41.
2006: Burns Wendy C; Twigg Stephen M; Forbes Josephine M; Pete Josefa; Tikellis Christos; Thallas-Bonke Vicki; Thomas Merlin C; Cooper Mark E; Kantharidis Phillip
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.
Journal of the American Society of Nephrology : JASN 2006;17(9):2484-94.
2006: Calkin Anna C; Giunti Sara; Jandeleit-Dahm Karin A; Allen Terri J; Cooper Mark E; Thomas Merlin C
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(9):2399-405.
2006: Tikellis C; Cooper M E; Bialkowski K; Johnston C I; Burns W C; Lew R A; Smith A I; Thomas M C
Developmental expression of ACE2 in the SHR kidney: a role in hypertension?
Kidney international 2006;70(1):34-41.
2006: Thomas M C; Cooper M E; Rossing K; Parving H H
Anaemia in diabetes: Is there a rationale to TREAT?
Diabetologia 2006;49(6):1151-7.
2006: Calkin A C; Cooper M E; Jandeleit-Dahm K A; Allen T J
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.
Diabetologia 2006;49(4):766-74.
2006: Cooper Mark E; Tikellis Chris; Thomas Merlin C
Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2006;24(1):S57-63.
2006: Gallicchio Marisa A; McRobert E Anne; Tikoo Anjali; Cooper Mark E; Bach Leon A
Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner.
Journal of the American Society of Nephrology : JASN 2006;17(2):414-21.
2006: Tikellis C; Cooper M E; Thomas M C
Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes.
The international journal of biochemistry & cell biology 2006;38(5-6):737-51.
2005: Cooper Mark E; Jandeleit-Dahm Karin A M
Lipids and diabetic renal disease.
Current diabetes reports 2005;5(6):445-8.
2005: Paizis G; Tikellis C; Cooper M E; Schembri J M; Lew R A; Smith A I; Shaw T; Warner F J; Zuilli A; Burrell L M; Angus P W
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2.
Gut 2005;54(12):1790-6.
2005: Dilley Rodney J; Farrelly Caroline A; Allen Terri J; Jandeleit-Dahm Karin; Cooper Mark E; Morahan Grant; Little Peter J
Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries.
Diabetes research and clinical practice 2005;70(3):201-8.
2005: Thomas Merlin C; Forbes Josephine M; Cooper Mark E
Advanced glycation end products and diabetic nephropathy.
American journal of therapeutics 2005;12(6):562-72.
2005: Jandeleit-Dahm Karin; Lassila Markus; Davis Belinda J; Candido Riccardo; Johnston Colin I; Allen Terri J; Burrell Louise M; Cooper Mark E
Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Journal of hypertension 2005;23(11):2071-82.
2005: Cooper Mark E; Jandeleit-Dahm Karin; Thomas Merlin C
Targets to retard the progression of diabetic nephropathy.
Kidney international 2005;68(4):1439-45.
2005: Thomas Merlin C; Tikellis Christos; Burns Wendy M; Bialkowski Katarzyna; Cao Zemin; Coughlan Melinda T; Jandeleit-Dahm Karen; Cooper Mark E; Forbes Josephine M
Interactions between renin angiotensin system and advanced glycation in the kidney.
Journal of the American Society of Nephrology : JASN 2005;16(10):2976-84.
2005: Calkin Anna C; Forbes Josephine M; Smith Craig M; Lassila Markus; Cooper Mark E; Jandeleit-Dahm Karin A; Allen Terri J
Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(9):1903-9.
2005: Kooptiwut Suwattanee; Kebede Melkam; Zraika Sakeneh; Visinoni Sherley; Aston-Mourney Kathryn; Favaloro Jenny; Tikellis Chris; Thomas Merlin C; Forbes Josephine M; Cooper Mark E; Dunlop Marjorie; Proietto Joseph; Andrikopoulos Sofianos
High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction.
Journal of molecular endocrinology 2005;35(1):39-48.
2005: Forbes Josephine M; Thorpe Suzanne R; Thallas-Bonke Vicki; Pete Josefa; Thomas Merlin C; Deemer Elizabeth R; Bassal Sahar; El-Osta Assam; Long David M; Panagiotopoulos Sianna; Jerums George; Osicka Tanya M; Cooper Mark E
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2005;16(8):2363-72.
2005: Coughlan Melinda T; Cooper Mark E; Forbes Josephine M
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Annals of the New York Academy of Sciences 2005;1043():750-8.
2005: McRobert E Anne; Tikoo Anjali; Gallicchio Marisa A; Cooper Mark E; Bach Leon A
Localization of the ezrin binding epitope for glycated proteins.
Annals of the New York Academy of Sciences 2005;1043():617-24.
2005: Bach Leon A; Gallicchio Marisa A; McRobert E Anne; Tikoo Anjali; Cooper Mark E
Effects of advanced glycation end products on ezrin-dependent functions in LLC-PK1 proximal tubule cells.
Annals of the New York Academy of Sciences 2005;1043():609-16.
2005: Levidiotis Vicki; Freeman Craig; Tikellis Chris; Cooper Mark E; Power David A
Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease.
Nephrology (Carlton, Vic.) 2005;10(2):167-73.
2005: Thomas M C; Burns W C; Cooper M E
Tubular changes in early diabetic nephropathy.
Advances in chronic kidney disease 2005;12(2):177-86.
2005: Fukami Kei; Cooper Mark E; Forbes Josephine M
Agents in development for the treatment of diabetic nephropathy.
Expert opinion on investigational drugs 2005;14(3):279-94.
2005: Thomas Merlin C; Cooper Mark E; Tsalamandris Con; MacIsaac Richard; Jerums George
Anemia with impaired erythropoietin response in diabetic patients.
Archives of internal medicine 2005;165(4):466-9.
2005: Burrell Louise M; Risvanis John; Kubota Eiji; Dean Rachael G; MacDonald Peter S; Lu Sai; Tikellis Christos; Grant Sharon L; Lew Rebecca A; Smith A Ian; Cooper Mark E; Johnston Colin I
Myocardial infarction increases ACE2 expression in rat and humans.
European heart journal 2005;26(4):369-75; discussion 322-4.
2005: Lassila Markus; Jandeleit-Dahm Karin; Seah Kwee K; Smith Craig M; Calkin Anna C; Allen Terri J; Cooper Mark E
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
Journal of the American Society of Nephrology : JASN 2005;16(2):363-73.
2005: Rizkalla Bishoy; Forbes Josephine M; Cao Zemin; Boner Geoffrey; Cooper Mark E
Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system.
Journal of hypertension 2005;23(1):153-64.
2004: Tikellis C; Johnston C I; Forbes J M; Burns W C; Thomas M C; Lew R A; Yarski M; Smith A I; Cooper M E
Identification of angiotensin converting enzyme 2 in the rodent retina.
Current eye research 2004;29(6):419-27.
2004: Cooper Mark E
The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
American journal of hypertension 2004;17(11 Pt 2):16S-20S; quiz A2-4.
2004: Thallas-Bonke Vicki; Lindschau Carsten; Rizkalla Bishoy; Bach Leon A; Boner Geoffrey; Meier Matthias; Haller Hermann; Cooper Mark E; Forbes Josephine M
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Diabetes 2004;53(11):2921-30.
2004: Jerums G; Allen T J; Campbell D J; Cooper M E; Gilbert R E; Hammond J J; O'Brien R C; Raffaele J; Tsalamandris C;
Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Diabetic medicine : a journal of the British Diabetic Association 2004;21(11):1192-9.
2004: Forbes Josephine M; Thomas Merlin C; Thorpe Suzanne R; Alderson Nathan L; Cooper Mark E
The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes.
Kidney international. Supplement 2004;(92):S105-7.
2004: Thomas Merlin C; Tikellis Christos; Kantharidis Phillip; Burns Wendy C; Cooper Mark E; Forbes Josephine M
The role of advanced glycation in reduced organic cation transport associated with experimental diabetes.
The Journal of pharmacology and experimental therapeutics 2004;311(2):456-66.
2004: Lassila Markus; Cooper Mark E; Jandeleit-Dahm Karin
Antiproteinuric effect of RAS blockade: new mechanisms.
Current hypertension reports 2004;6(5):383-92.
2004: Thomas Merlin C; Tsalamandris Con; MacIsaac Richard; Medley Tanya; Kingwell Bronwyn; Cooper Mark E; Jerums George
Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes.
Kidney international 2004;66(3):1167-72.
2004: Ma Guorong; Allen Terri J; Cooper Mark E; Cao Zemin
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
Kidney international 2004;66(3):1090-8.
2004: Lee Fiona T H; Cao Zemin; Long David M; Panagiotopoulos Sianna; Jerums George; Cooper Mark E; Forbes Josephine M
Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2004;15(8):2139-51.
2004: Lassila Markus; Seah Kwee K; Allen Terri J; Thallas Vicki; Thomas Merlin C; Candido Riccardo; Burns Wendy C; Forbes Josephine M; Calkin Anna C; Cooper Mark E; Jandeleit-Dahm Karin A M
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.
Journal of the American Society of Nephrology : JASN 2004;15(8):2125-38.
2004: Forbes Josephine M; Yee Louis Teo Loon; Thallas Vicki; Lassila Markus; Candido Riccardo; Jandeleit-Dahm Karin A; Thomas Merlin C; Burns Wendy C; Deemer Elizabeth K; Thorpe Susan R; Cooper Mark E; Allen Terri J
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
Diabetes 2004;53(7):1813-23.
2004: Wigg S J; Tare M; Forbes J; Cooper M E; Thomas M C; Coleman H A; Parkington H C; O'Brien R C
Early vitamin E supplementation attenuates diabetes-associated vascular dysfunction and the rise in protein kinase C-beta in mesenteric artery and ameliorates wall stiffness in femoral artery of Wistar rats.
Diabetologia 2004;47(6):1038-46.
2004: Twigg S M; Cooper M E
The time has come to target connective tissue growth factor in diabetic complications.
Diabetologia 2004;47(6):965-8.
2004: Burrell Louise M; Johnston Colin I; Tikellis Christos; Cooper Mark E
ACE2, a new regulator of the renin-angiotensin system.
Trends in endocrinology and metabolism: TEM 2004;15(4):166-9.
2004: Lassila Markus; Allen Terri J; Cao Zemin; Thallas Vicki; Jandeleit-Dahm Karin A; Candido Riccardo; Cooper Mark E
Imatinib attenuates diabetes-associated atherosclerosis.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(5):935-42.
2004: Tikellis Christos; Wookey Peter J; Candido Riccardo; Andrikopoulos Sof; Thomas Merlin C; Cooper Mark E
Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.
Diabetes 2004;53(4):989-97.
2004: Candido Riccardo; Allen Terri J; Lassila Markus; Cao Zemin; Thallas Vicki; Cooper Mark E; Jandeleit-Dahm Karin A
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Circulation 2004;109(12):1536-42.
2004: Brasier Geoffrey; Tikellis Christos; Xuereb Loredanna; Craigie Jillian; Casley David; Kovacs Christopher S; Fudge Neva J; Kalnins Renate; Cooper Mark E; Wookey Peter J
Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis.
Experimental cell research 2004;293(1):31-42.
2004: Tikellis Christos; Cooper Mark E; Twigg Stephen M; Burns Wendy C; Tolcos Mary
Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition.
Endocrinology 2004;145(2):860-6.
2004: MacIsaac Richard J; Jerums George; Cooper Mark E
New insights into the significance of microalbuminuria.
Current opinion in nephrology and hypertension 2004;13(1):83-91.
2004: Mifsud Sally A; Burrell Louise M; Kubota Eiji; Jaworski Kassie; Cooper Mark E; Wilkinson-Berka Jennifer L
Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Clinical and experimental hypertension (New York, N.Y. : 1993) 2004;26(1):69-80.
2004: Levidiotis Vicki; Freeman Craig; Tikellis Chris; Cooper Mark E; Power David A
Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis.
Journal of the American Society of Nephrology : JASN 2004;15(1):68-78.
2004: Davis B J; Forbes J M; Thomas M C; Jerums G; Burns W C; Kawachi H; Allen T J; Cooper M E
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat.
Diabetologia 2004;47(1):89-97.
2004: Forbes Josephine M; Thallas-Bonke Vicki; Cooper Mark E; Thomas Merlin C
Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy.
Current pharmaceutical design 2004;10(27):3361-72.
2004: Kanellis John; Levidiotis Vicki; Khong Tiffany; Cox Alison J; Stacker Steven A; Gilbert Richard E; Cooper Mark E; Power David A
A study of VEGF and its receptors in two rat models of proteinuria.
Nephron. Physiology 2004;96(1):P26-36.
2003: Rizkalla Bishoy; Forbes Josephine M; Cooper Mark E; Cao Zemin
Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors.
Journal of the American Society of Nephrology : JASN 2003;14(12):3061-71.
2003: Forbes Josephine M; Thallas Vicki; Thomas Merlin C; Founds Hank W; Burns Wendy C; Jerums George; Cooper Mark E
The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(12):1762-4.
2003: Sarlos Stella; Rizkalla Bishoy; Moravski Christina J; Cao Zemin; Cooper Mark E; Wilkinson-Berka Jennifer L
Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin.
The American journal of pathology 2003;163(3):879-87.
2003: MacIsaac Richard J; Cooper Mark E
Microalbuminuria and diabetic cardiovascular disease.
Current atherosclerosis reports 2003;5(5):350-7.
2003: Forbes Josephine M; Cooper Mark E; Oldfield Matthew D; Thomas Merlin C
Role of advanced glycation end products in diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2003;14(8 Suppl 3):S254-8.
2003: Davis B J; Johnston C I; Burrell L M; Burns W C; Kubota E; Cao Z; Cooper M E; Allen T J
Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.
Diabetologia 2003;46(7):961-71.
2003: McRobert E Anne; Gallicchio Marisa; Jerums George; Cooper Mark E; Bach Leon A
The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications.
The Journal of biological chemistry 2003;278(28):25783-9.
2003: Thomas Merlin C; Tikellis Chris; Burns Wendy C; Thallas Vicki; Forbes Josephine M; Cao Zemin; Osicka Tanya M; Russo Leileata M; Jerums George; Ghabrial Hany; Cooper Mark E; Kantharidis Phillip
Reduced tubular cation transport in diabetes: prevented by ACE inhibition.
Kidney international 2003;63(6):2152-61.
2003: Calkin Anna C; Thomas Merlin C; Cooper Mark E
MK-767. Kyorin/Banyu/Merck.
Current opinion in investigational drugs (London, England : 2000) 2003;4(4):444-8.
2003: Lassila Markus; Davis Belinda J; Allen Terri J; Burrell Louise M; Cooper Mark E; Cao Zemin
Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Clinical science (London, England : 1979) 2003;104(4):341-7.
2003: Candido Riccardo; Forbes Josephine M; Thomas Merlin C; Thallas Vicki; Dean Rachael G; Burns Wendy C; Tikellis Christos; Ritchie Rebecca H; Twigg Stephen M; Cooper Mark E; Burrell Louise M
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
Circulation research 2003;92(7):785-92.
2003: Wookey Peter J; Xuereb Loredanna; Tikellis Christos; Cooper Mark E
Amylin in the periphery.
TheScientificWorldJournal 2003;3():163-75.
2003: Bui B V; Armitage J A; Tolcos M; Cooper M E; Vingrys A J
ACE inhibition salvages the visual loss caused by diabetes.
Diabetologia 2003;46(3):401-8.
2003: Tikellis Christos; Johnston Colin I; Forbes Josephine M; Burns Wendy C; Burrell Louise M; Risvanis John; Cooper Mark E
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.
Hypertension 2003;41(3):392-7.
2003: Tikellis Christos; Xuereb Loredanna; Casley David; Brasier Geoffrey; Cooper Mark E; Wookey Peter J
Calcitonin receptor isoforms expressed in the developing rat kidney.
Kidney international 2003;63(2):416-26.
2003: Davis Belinda J; Cao Zemin; de Gasparo Marc; Kawachi Hiroshi; Cooper Mark E; Allen Terri J
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Journal of hypertension 2003;21(1):209-16.
2003: Moravski Christina J; Skinner Sandford L; Stubbs Anthony J; Sarlos Stella; Kelly Darren J; Cooper Mark E; Gilbert Richard E; Wilkinson-Berka Jennifer L
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies.
The American journal of pathology 2003;162(1):151-60.
2002: Twigg Stephen M; Cao Zemin; MCLennan Sue V; Burns Wendy C; Brammar Gail; Forbes Josephine M; Cooper Mark E
Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine.
Endocrinology 2002;143(12):4907-15.
2002: Paizis Georgina; Cooper Mark E; Schembri Josefa M; Tikellis Christos; Burrell Louise M; Angus Peter W
Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver.
Gastroenterology 2002;123(5):1667-76.
2002: Wilkinson-Berka Jennifer L; Kelly Darren J; Koerner Suzanne M; Jaworski Kassie; Davis Belinda; Thallas Vicki; Cooper Mark E
ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.
Diabetes 2002;51(11):3283-9.
2002: Forbes Josephine M; Cooper Mark E; Thallas Vicki; Burns Wendy C; Thomas Merlin C; Brammar Gail C; Lee Fiona; Grant Sharon L; Burrell Louise A; Jerums George; Osicka Tanya M
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.
Diabetes 2002;51(11):3274-82.
2002: Cooper Mark E; Mundel Peter; Boner Geoffrey
Role of nephrin in renal disease including diabetic nephropathy.
Seminars in nephrology 2002;22(5):393-8.
2002: Bonnet Fabrice; Candido Riccardo; Carey Robert M; Casley David; Russo Leileata M; Osicka Tanya M; Cooper Mark E; Cao Zemin
Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.
Journal of hypertension 2002;20(8):1615-24.
2002: Bonnet Fabrice; Tikellis Christos; Kawachi Hiroshi; Burns Wendy C; Wookey Peter J; Cao Zemin; Cooper Mark E
Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats.
Clinical and experimental hypertension (New York, N.Y. : 1993) 2002;24(5):371-81.
2002: Candido Riccardo; Jandeleit-Dahm Karin A; Cao Zemin; Nesteroff Stefan P; Burns Wendy C; Twigg Stephen M; Dilley Rodney J; Cooper Mark E; Allen Terri J
Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice.
Circulation 2002;106(2):246-53.
2002: Cao Zemin; Bonnet Fabrice; Candido Riccardo; Nesteroff Stefan P; Burns Wendy C; Kawachi Hiroshi; Shimizu Fujio; Carey Robert M; De Gasparo Marc; Cooper Mark E
Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.
Journal of the American Society of Nephrology : JASN 2002;13(7):1773-87.
2002: Houlihan Christine A; Akdeniz Aysel; Tsalamandris Con; Cooper Mark E; Jerums George; Gilbert Richard E
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
Diabetes care 2002;25(6):1072-7.
2002: Forbes Josephine M; Bonnet Fabrice; Russo Leileata M; Burns Wendy C; Cao Zemin; Candido Riccardo; Kawachi Hiroshi; Allen Terri J; Cooper Mark E; Jerums George; Osicka Tanya M
Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria.
Journal of hypertension 2002;20(5):985-92.
2002: Houlihan Christine A; Allen Terri J; Baxter Amynta L; Panangiotopoulos Sianna; Casley David J; Cooper Mark E; Jerums George
A low-sodium diet potentiates the effects of losartan in type 2 diabetes.
Diabetes care 2002;25(4):663-71.
2002: Tikkanen Ilkka; Tikkanen Tuula; Cao Zemin; Allen Terri J; Davis Belinda J; Lassila Markus; Casley David; Johnston Colin I; Burrell Louise M; Cooper Mark E
Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Journal of hypertension 2002;20(4):707-14.
2002: Candido Riccardo; Fabris Bruno; Cooper Mark E
Treatment for diabetic nephropathy - a review of the recent patent literature.
IDrugs : the investigational drugs journal 2002;5(3):237-65.
2002: Mifsud Sally A; Skinner Sandford L; Cooper Mark E; Kelly Darren J; Wilkinson-Berka Jennifer L
Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.
Journal of the American Society of Nephrology : JASN 2002;13(3):684-92.
2002: Kelly Darren J; Cox Alison J; Tolcos Mary; Cooper Mark E; Wilkinson-Berka Jennifer L; Gilbert Richard E
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
Kidney international 2002;61(1):31-9.
2001: Oldfield M D; Bach L A; Forbes J M; Nikolic-Paterson D; McRobert A; Thallas V; Atkins R C; Osicka T; Jerums G; Cooper M E
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).
The Journal of clinical investigation 2001;108(12):1853-63.
2001: Cooper M E
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.
Diabetologia 2001;44(11):1957-72.
2001: Cao Z; Cooper M E
Role of angiotensin II in tubulointerstitial injury.
Seminars in nephrology 2001;21(6):554-62.
2001: Kelly D J; Gilbert R E; Cox A J; Soulis T; Jerums G; Cooper M E
Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2001;12(10):2098-107.
2001: Paizis G; Gilbert R E; Cooper M E; Murthi P; Schembri J M; Wu L L; Rumble J R; Kelly D J; Tikellis C; Cox A; Smallwood R A; Angus P W
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.
Journal of hepatology 2001;35(3):376-85.
2001: Cao Z; Burrell L M; Tikkanen I; Bonnet F; Cooper M E; Gilbert R E
Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Kidney international 2001;60(2):715-21.
2001: Mifsud S A; Allen T J; Bertram J F; Hulthen U L; Kelly D J; Cooper M E; Wilkinson-Berka J L; Gilbert R E
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Diabetologia 2001;44(7):878-82.
2001: Bonnet F; Cooper M E; Kawachi H; Allen T J; Boner G; Cao Z
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
Diabetologia 2001;44(7):874-7.
2001: Wilkinson-Berka J L; Gibbs N J; Cooper M E; Skinner S L; Kelly D J
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2001;16(7):1343-9.
2001: Bonnet F; Cooper M E; Carey R M; Casley D; Cao Z
Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion.
Journal of hypertension 2001;19(6):1075-81.
2001: Cao Z; Bonnet F; Davis B; Allen T J; Cooper M E
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
Clinical science (London, England : 1979) 2001;100(6):591-9.
2001: Cooper M E; Bonnet F; Oldfield M; Jandeleit-Dahm K
Mechanisms of diabetic vasculopathy: an overview.
American journal of hypertension 2001;14(5 Pt 1):475-86.
2001: Jerums G; Allen T J; Campbell D J; Cooper M E; Gilbert R E; Hammond J J; Raffaele J; Tsalamandris C
Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;37(5):890-9.
2001: Gilbert R E; Kelly D J; McKay T; Chadban S; Hill P A; Cooper M E; Atkins R C; Nikolic-Paterson D J
PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis.
Kidney international 2001;59(4):1324-32.
2001: Forbes J M; Soulis T; Thallas V; Panagiotopoulos S; Long D M; Vasan S; Wagle D; Jerums G; Cooper M E
Renoprotective effects of a novel inhibitor of advanced glycation.
Diabetologia 2001;44(1):108-14.
2001: Cooper M E; Webb R L; de Gasparo M
Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?
Cardiovascular drug reviews 2001;19(1):75-86.
2000: Moravski C J; Kelly D J; Cooper M E; Gilbert R E; Bertram J F; Shahinfar S; Skinner S L; Wilkinson-Berka J L
Retinal neovascularization is prevented by blockade of the renin-angiotensin system.
Hypertension 2000;36(6):1099-104.
2000: Cao Z; Kelly D J; Cox A; Casley D; Forbes J M; Martinello P; Dean R; Gilbert R E; Cooper M E
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.
Kidney international 2000;58(6):2437-51.
2000: Jandeleit-Dahm K; Hannan K M; Farrelly C A; Allen T J; Rumble J R; Gilbert R E; Cooper M E; Little P J
Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition.
Circulation research 2000;87(12):1133-40.
2000: Gilbert R E; Kelly D J; Cox A J; Wilkinson-Berka J L; Rumble J R; Osicka T; Panagiotopoulos S; Lee V; Hendrich E C; Jerums G; Cooper M E
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.
Diabetologia 2000;43(11):1360-7.
2000: Cao Z; Cooper M E; Wu L L; Cox A J; Jandeleit-Dahm K; Kelly D J; Gilbert R E
Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
Hypertension 2000;36(4):561-8.
2000: Cooper M E; Thallas V; Forbes J; Scalbert E; Sastra S; Darby I; Soulis T
The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.
Diabetologia 2000;43(5):660-4.
2000: Kelly D J; Skinner S L; Gilbert R E; Cox A J; Cooper M E; Wilkinson-Berka J L
Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat.
Kidney international 2000;57(5):1882-94.
2000: Bach L A; Dean R; Youssef S; Cooper M E
Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2000;15(3):347-54.
2000: Gilbert R E; Rumble J R; Cao Z; Cox A J; van Eeden P; Allen T J; Kelly D J; Cooper M E
Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes.
Circulation research 2000;86(2):158-65.
2000: Jandeleit-Dahm K; Allen T J; Youssef S; Gilbert R E; Cooper M E
Is there a role for endothelin antagonists in diabetic renal disease?
Diabetes, obesity & metabolism 2000;2(1):15-24.
2000: Jandeleit-Dahm K; Rumble J; Cox A J; Kelly D J; Dziadek M; Cooper M E; Gilbert R E
SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy.
Microvascular research 2000;59(1):61-71.
1999: Gilbert R E; Cooper M E
The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?
Kidney international 1999;56(5):1627-37.
1999: Cooper M E; Vranes D; Youssef S; Stacker S A; Cox A J; Rizkalla B; Casley D J; Bach L A; Kelly D J; Gilbert R E
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.
Diabetes 1999;48(11):2229-39.
1999: Cao Z; Dean R; Wu L; Casley D; Cooper M E
Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy.
Hypertension 1999;34(3):408-14.
1999: Gilbert R E; Wu L L; Kelly D J; Cox A; Wilkinson-Berka J L; Johnston C I; Cooper M E
Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis.
The American journal of pathology 1999;155(2):429-40.
1999: Jandeleit-Dahm K; Cao Z; Cox A J; Kelly D J; Gilbert R E; Cooper M E
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Kidney international. Supplement 1999;71():S31-6.
1999: Campbell D J; Kelly D J; Wilkinson-Berka J L; Cooper M E; Skinner S L
Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats.
Kidney international 1999;56(1):211-21.
1999: Soulis T; Sastra S; Thallas V; Mortensen S B; Wilken M; Clausen J T; Bjerrum O J; Petersen H; Lau J; Jerums G; Boel E; Cooper M E
A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes.
Diabetologia 1999;42(4):472-9.
1999: Youssef S; Nguyen D T; Soulis T; Panagiotopoulos S; Jerums G; Cooper M E
Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding.
Kidney international 1999;55(3):907-16.
1999: Vranes D; Cooper M E; Dilley R J
Cellular mechanisms of diabetic vascular hypertrophy.
Microvascular research 1999;57(1):8-18.
1999: Boner G; Cooper M E
Diabetic nephropathy.
Diabetes technology & therapeutics 1999;1(4):489-96.
1999: Gilbert R E; Cox A J; Kelly D J; Wilkinson-Berka J L; Sage E H; Jerums G; Cooper M E
Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye.
Connective tissue research 1999;40(4):295-303.
1998: Roufail E; Soulis T; Boel E; Cooper M E; Rees S
Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine.
Diabetologia 1998;41(12):1419-25.
1998: Cooper M E; Cao Z; Rumble J R; Jandeleit K; Allen T J; Gilbert R E
Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies.
Metabolism: clinical and experimental 1998;47(12 Suppl 1):24-7.
1998: Cooper M E; Gilbert R E; Epstein M
Pathophysiology of diabetic nephropathy.
Metabolism: clinical and experimental 1998;47(12 Suppl 1):3-6.
1998: Yu H C; Burrell L M; Black M J; Wu L L; Dilley R J; Cooper M E; Johnston C I
Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats.
Circulation 1998;98(23):2621-8.
1998: Rumble J R; Gilbert R E; Cox A; Wu L; Cooper M E
Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.
Journal of hypertension 1998;16(11):1603-9.
1998: Youssef S; Soulis T; Cooper M E
Hepatic advanced glycation endproduct binding is increased in experimental diabetes.
Cellular and molecular biology (Noisy-le-Grand, France) 1998;44(7):1095-100.
1998: Tikkanen T; Tikkanen I; Rockell M D; Allen T J; Johnston C I; Cooper M E; Burrell L M
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Hypertension 1998;32(4):778-85.
1998: Gilbert R E; Wilkinson-Berka J L; Johnson D W; Cox A; Soulis T; Wu L L; Kelly D J; Jerums G; Pollock C A; Cooper M E
Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats.
Kidney international 1998;54(4):1052-62.
1998: Wookey P J; Cooper M E
Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension.
Clinical and experimental pharmacology & physiology 1998;25(9):653-60.
1998: Gilbert R E; Vranes D; Berka J L; Kelly D J; Cox A; Wu L L; Stacker S A; Cooper M E
Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
Laboratory investigation; a journal of technical methods and pathology 1998;78(8):1017-27.
1998: Kelly D J; Wilkinson-Berka J L; Allen T J; Cooper M E; Skinner S L
A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR).
Kidney international 1998;54(2):343-52.
1998: Cao Z; Hulthén U L; Allen T J; Cooper M E
Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.
Journal of hypertension 1998;16(6):793-9.
1998: Gilbert R E; Cox A; Wu L L; Allen T J; Hulthen U L; Jerums G; Cooper M E
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
Diabetes 1998;47(3):414-22.
1998: Panagiotopoulos S; O'Brien R C; Bucala R; Cooper M E; Jerums G
Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit.
Atherosclerosis 1998;136(1):125-31.
1998: Wookey P J; Tikellis C; Nobes M; Casley D; Cooper M E; Darby I A
Amylin as a growth factor during fetal and postnatal development of the rat kidney.
Kidney international 1998;53(1):25-30.
1998: Wookey P J; Cao Z; Cooper M E
Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension.
Mineral and electrolyte metabolism 1998;24(6):389-99.
1997: Wu L L; Yang N; Roe C J; Cooper M E; Gilbert R E; Atkins R C; Lan H Y
Macrophage and myofibroblast proliferation in remnant kidney: role of angiotensin II.
Kidney international. Supplement 1997;63():S221-5.
1997: Cao Z; Wookey P J; Wu L L; Voskuil M; van Geenen R C; Cooper M E
Renal amylin binding in normotensive and hypertensive rats: effects of angiotensin converting enzyme inhibition with perindopril.
Journal of hypertension 1997;15(11):1245-52.
1997: Soulis T; Cooper M E; Sastra S; Thallas V; Panagiotopoulos S; Bjerrum O J; Jerums G
Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats.
Diabetologia 1997;40(10):1141-51.
1997: Allen T J; Cao Z; Youssef S; Hulthen U L; Cooper M E
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Diabetes 1997;46(10):1612-8.
1997: Cooper M E; Gilbert R E; Jerums G
Diabetic vascular complications.
Clinical and experimental pharmacology & physiology 1997;24(9-10):770-5.
1997: Wookey P J; Cao Z; van Geenen R C; Voskuil M; Darby I A; Komers R; Cooper M E
Increased density of renal amylin binding sites in experimental hypertension.
Hypertension 1997;30(3 Pt 1):455-60.
1997: Wu L L; Cox A; Roe C J; Dziadek M; Cooper M E; Gilbert R E
Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system.
Journal of the American Society of Nephrology : JASN 1997;8(9):1373-82.
1997: Cooper M E
Antihypertensive therapy and diabetic microvascular disease.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1997;19(5-6):769-78.
1997: Gilbert R E; Cox A; McNally P G; Wu L L; Dziadek M; Cooper M E; Jerums G
Increased epidermal growth factor in experimental diabetes related kidney growth in rats.
Diabetologia 1997;40(7):778-85.
1997: Soulis T; Thallas V; Youssef S; Gilbert R E; McWilliam B G; Murray-McIntosh R P; Cooper M E
Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
Diabetologia 1997;40(6):619-28.
1997: Wu L L; Cox A; Roe C J; Dziadek M; Cooper M E; Gilbert R E
Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system.
Kidney international 1997;51(5):1553-67.
1997: Haynes J M; Hodgson W C; Cooper M E
Rat amylin mediates a pressor response in the anaesthetised rat: implications for the association between hypertension and diabetes mellitus.
Diabetologia 1997;40(3):256-61.
1997: Rumble J R; Cooper M E; Soulis T; Cox A; Wu L; Youssef S; Jasik M; Jerums G; Gilbert R E
Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.
The Journal of clinical investigation 1997;99(5):1016-27.
1997: Harris P J; Cooper M E; Hiranyachattada S; Berka J L; Kelly D J; Nobes M; Wookey P J
Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney.
The American journal of physiology 1997;272(1 Pt 2):F13-21.
1997: Allen T J; Waldron M J; Casley D; Jerums G; Cooper M E
Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes.
Diabetes 1997;46(1):19-24.
1996: Hulthén U L; Cao Z; Rumble J R; Cooper M E; Johnston C I
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
American journal of hypertension 1996;9(9):895-901.
1996: Allen T J; Cooper M E; Gilbert R E; Winikoff J; Skinni S L; Jerums G
Serum total renin is increased before microalbuminuria in diabetes.
Kidney international 1996;50(3):902-7.
1996: Soulis T; Cooper M E; Vranes D; Bucala R; Jerums G
Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.
Kidney international 1996;50(2):627-34.
1996: Rumble J R; Komers R; Cooper M E
Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
Journal of hypertension 1996;14(5):601-7.
1996: Wookey P J; Tikellis C; Du H C; Qin H F; Sexton P M; Cooper M E
Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin.
The American journal of physiology 1996;270(2 Pt 2):F289-94.
1996: Cooper M E; Vranes D; Rumble J R
Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life.
Drugs & aging 1996;8(1):38-46.
1995: Allen T J; Hulthen U L; Rumble J R; Jasik M; Cooper M E
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.
Journal of diabetes and its complications 1995;9(4):318-22.
1995: Jerums G; Allen T J; Gilbert R E; Hammond J; Cooper M E; Campbell D J; Raffaele J
Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group.
Journal of diabetes and its complications 1995;9(4):308-14.
1995: Vranes D; Dilley R J; Cooper M E
Vascular changes in the diabetic kidney: effects of ACE inhibition.
Journal of diabetes and its complications 1995;9(4):296-300.
1995: Gilbert R E; McNally P G; Cox A; Dziadek M; Rumble J; Cooper M E; Jerums G
SPARC gene expression is reduced in early diabetes-related kidney growth.
Kidney international 1995;48(4):1216-25.
1995: Gilbert R E; Jasik M; DeLuise M; O'Callaghan C J; Cooper M E
Diabetes and hypertension. Australian Diabetes Society position statement.
The Medical journal of Australia 1995;163(7):372-5.
1995: Cooper M E; McNally P G; Phillips P A; Johnston C I
Amylin stimulates plasma renin concentration in humans.
Hypertension 1995;26(3):460-4.
1995: Haynes J M; Cooper M E
Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects.
European journal of pharmacology 1995;280(1):91-4.
1995: Vranes D; Cooper M E; Dilley R J
Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies.
Journal of vascular research 1995;32(3):183-9.
1995: Hulthén U L; Rumble J; Cooper M E; Johnston C I
Vascular albumin permeability and hypertrophy in a rat model combining streptozotocin-induced diabetes and genetic hypertension.
Journal of hypertension 1995;13(5):529-33.
1995: Soulis-Liparota T; Cooper M E; Dunlop M; Jerums G
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Diabetologia 1995;38(4):387-94.
1995: Komers R; Cooper M E
Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
The American journal of physiology 1995;268(4 Pt 2):F588-94.
1995: Rumble J R; Doyle A E; Cooper M E
Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes.
American journal of hypertension 1995;8(1):53-7.
1994: Cooper M E; Rumble J; Komers R; Du H C; Jandeleit K; Chou S T
Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition.
Diabetes 1994;43(10):1221-8.
1994: Komers R; Allen T J; Cooper M E
Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes.
Diabetes 1994;43(10):1190-7.
1994: Tsalamandris C; Panagiotopoulos S; Sinha A; Cooper M E; Jerums G
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Journal of cardiovascular risk 1994;1(3):231-9.
1994: Gilbert R E; Cooper M E; McNally P G; O'Brien R C; Taft J; Jerums G
Microalbuminuria: prognostic and therapeutic implications in diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association 1994;11(7):636-45.
1994: Tsalamandris C; Allen T J; Gilbert R E; Sinha A; Panagiotopoulos S; Cooper M E; Jerums G
Progressive decline in renal function in diabetic patients with and without albuminuria.
Diabetes 1994;43(5):649-55.
1994: Bach L A; Cooper M E; Vranes D; Allen T J; Rumble J; Jerums G
Disparate effects of castration on renal structure and function in the streptozotocin diabetic rat.
Diabetes research (Edinburgh, Scotland) 1994;27(1):27-38.
1993: Jerums G; Allen T J; Tsalamandris C; Akdeniz A; Sinha A; Gilbert R; Cooper M E
Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.
Diabetologia 1993;36(10):1037-44.
1993: Bach L A; Gilbert R E; Cooper M E; Tsalamandris C; Jerums G
Prediction of persistent microalbuminuria in patients with diabetes mellitus.
Journal of diabetes and its complications 1993;7(2):67-72.
1993: O'Brien R C; Cooper M E; Jerums G; Doyle A E
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
Diabetes 1993;42(4):604-9.
1993: Cooper M E; Vranes D; Vranes D A; Allen T J; Panagiotopoulos S; Komers R; Jerums G
The effects of dietary cholesterol on experimental diabetic nephropathy.
Diabetes research (Edinburgh, Scotland) 1993;22(4):159-69.
1992: Cooper M E; Doyle A E
The management of diabetic proteinuria. Which antihypertensive agent?
Drugs & aging 1992;2(4):301-9.
1992: Jandeleit K; Rumble J; Jackson B; Cooper M E
Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus.
Clinical and experimental pharmacology & physiology 1992;19(5):343-7.
1992: Jerums G; Allen T J; Tsalamandris C; Cooper M E
Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group.
Kidney international 1992;41(4):904-11.
1992: Cooper M E; Rumble J R; Allen T J; O'Brien R C; Jerums G; Doyle A E
Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
Kidney international 1992;41(4):898-903.
1992: Johnston C I; Cooper M E; Nicholls G M
Meeting report of the International Society of Hypertension Conference on Hypertension and Diabetes.
Journal of hypertension 1992;10(4):393-7.
1992: Cooper M E; Rumble J R; Gin T; Lim-Joon T
Diabetic renal microvascular disease: the role of hypertension and ACE inhibitors.
Clinical and experimental pharmacology & physiology. Supplement 1992;19():23-7.
1991: O'Brien R C; Cooper M E; Murray R M; Seeman E; Thomas A K; Jerums G
Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
The Journal of clinical endocrinology and metabolism 1991;72(5):1008-13.
1990: Cooper M E; Allen T J; O'Brien R C; Papazoglou D; Clarke B E; Jerums G; Doyle A E
Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Diabetes 1990;39(12):1575-9.
1990: Allen T J; Cooper M E; O'Brien R C; Bach L A; Jackson B; Jerums G
Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy.
Diabetes 1990;39(10):1182-90.
1990: O'Brien R C; Simons L A; Clifton P; Cooper M E; Jennings G L; Jerums G; Nestel P J; Sullivan D
Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia.
The Medical journal of Australia 1990;152(9):480-3.
1990: Cooper M E; Vranes D A; Panagiotopoulos S; Allen T J; Goodall I; Jerums G
Hyperlipidaemia increases albuminuria in hypertensive and normotensive rats.
Clinical and experimental pharmacology & physiology 1990;17(3):225-8.
1990: Bach L A; Cooper M E; O'Brien R C; Jerums G
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Journal of the American Geriatrics Society 1990;38(1):10-4.
1989: Jerums G; Allen T J; Cooper M E
Triphasic changes in selectivity with increasing proteinuria in type 1 and type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 1989;6(9):772-9.
1989: O'Brien R C; Cooper M E; Allen T J; Jerums G
Ramipril reduces albuminuria in diabetic rats fed a high protein diet.
Clinical and experimental pharmacology & physiology 1989;16(8):675-80.
1989: Cooper M E; Allen T J; Macmillan P A; Clarke B E; Jerums G; Doyle A E
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat.
Diabetologia 1989;32(5):326-8.
1989: Cooper M E; O'Brien R C; Murray R M; Seeman E; Jerums G
Intermittent diabetic microalbuminuria: association with blood pressure, glycemic control, and protein intake.
The Journal of diabetic complications 1989;3(2):92-8.
1988: Cooper M E; Allen T J; O'Brien R C; Macmillan P A; Clarke B; Jerums G; Doyle A E
Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics.
Journal of hypertension 1988;6(12):1009-16.
1988: Cooper M E; Frauman A; O'Brien R C; Seeman E; Murray R M; Jerums G
Progression of proteinuria in type 1 and type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 1988;5(4):361-8.
1988: O'Brien R C; Allen T J; Cooper M E; Bach L; Jerums G
Glomerular filtration rate in early experimental diabetes.
The Journal of diabetic complications 1988;2(1):8-11.
1988: Cooper M E; Allen T J; Macmillan P; Bach L; Jerums G; Doyle A E
Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat.
American journal of hypertension 1988;1(1):5-10.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Mark Cooper

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Mark Cooper (preview)

All Publications